Jaguar Health, Inc. (JAGX) intrinsic value & 10-year financials
Jaguar Health, Inc. (JAGX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 63.0% a year to $11.5M, with an average return on invested capital of 178.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.53
- Market cap
- $8.2M
- Revenue (FY2025)
- $11.5M
- Revenue growth (10-yr CAGR)
- 63.0%
- ROIC (10-yr avg)
- 178.9%
- Free cash flow (FY2025)
- —
JAGX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $11.5M | -$53.6M | -$22.97 | — | -398.8% | 468.8% |
| FY2024 | $11.7M | -$38.5M | -$16.34 | -$29.4M | -263.8% | 4089.0% |
| FY2023 | $9.8M | -$41.3M | -$0.22 | — | -351.3% | 1010.6% |
| FY2022 | $12.0M | -$47.5M | -$0.25 | -$33.2M | -287.8% | 663.2% |
| FY2021 | $4.3M | -$52.6M | -$0.01 | -$35.0M | -939.1% | 951.3% |
| FY2020 | $9.4M | -$33.8M | -$0.02 | -$15.3M | -283.9% | -191.2% |
| FY2019 | $5.8M | -$38.5M | — | — | -501.2% | -360.6% |
| FY2018 | $4.4M | -$32.1M | — | -$22.7M | -698.0% | -175.2% |
| FY2017 | $4.4M | -$22.0M | — | — | -785.3% | -229.1% |
| FY2016 | $141.5K | -$14.7M | — | -$14.5M | -9599.8% | -4437.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Jaguar Health, Inc. is a consistent compounder, expanding top-line revenue at 63.0% annually over the past decade.
Jaguar Health, Inc. has historically struggled to out-earn its cost of capital, averaging just 1.8% ROIC.
Jaguar Health, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Jaguar Health, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-762.96 per share.